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for reducing thrombotic risk and fatigue in jSLE patients. Fur-
ther studies are needed to address this issue.
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Background Antiphospholipid Syndrome (APS) is a known
cause of thrombotic disorders, including Acute Myocardial
Infarction (AMI). Although its incidence in AMI patients is
not known, it may be an important factor in precipitating
infarction, especially in younger adults.
Methods This is a case-control study consisting in 73 patients
with Acute Myocardial Infarction, hospitalized at Cardiovascu-
lar Reanimation Clinic from 10 December 2015- 10 October
2019. All patients included in the study were from 23 to 50
years old. In the case-group were included 24 patients with
Antiphospholipid Syndrome and Acute Myocardial Infarction,
and 49 patients were included in the control group, which
consisted only in patients with AMI, with no presence of
APS. In every patient were gathered data such as complete
blood count + ESR, Antinuclear Antibodies (ANA), Anti-cardi-
olipin antibodies (ACA), C3 and C4 complement fraction,
Anti-ds-DNA, CRP and Ejection Fraction (EF) in echocardiog-
raphy. Female patients were asked about their abortion history.
As recommended in the guidelines, in positive results for APS,
ACA levels were repeated after 12 weeks in order to establish
the diagnosis. All data were gathered and statistically analyzed
using Excel 2010 and IBM SPSS.
Results After comparing all gathered data, it was found that
the patients with APS and AMI had a more significant ten-
dency to have C3 hypocomplementemia (p=0.006), thrombo-
cytopenia (p=0.002), a lower ejection fraction on
transthoracic echocardiography (p=0.04) and a more elevated
number of abortions before acute myocardial infarction
(p=0.03) in comparison to the controls.
Conclusions From our study it was found that APS is not rare
in young adults with AMI. It should be always suspected in
young patients with no cardiovascular risk factors and there
may be a characteristic clinical and laboratory picture in
patients with AMI, which may suggest the APS diagnosis.
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Purpose This study aims to gain insight into the care provided
to patients with antiphospholipid syndrome (APS) in The
Netherlands and to identify areas for improvement from the
perspective of both patients and clinicians.
Methods APS care was evaluated using qualitative and quanti-
tative methods. Perspectives on APS care were identified using
semi-structured interviews with medical specialists, patient
focus groups and a cross-sectional, online patient survey. In
order to examine differences in medical practice, medical
records were reviewed retrospectively regarding clinical and
laboratory manifestations, pharmacological treatment and man-
agement of disease in six hospitals throughout The
Netherlands.
Results Fourteen interviewed medical specialists, fourteen focus
group participants and 79 survey respondents participated in
the study. 237 patients were included in medical record
review. Only one-third of patients were diagnosed with APS
within three months after entering specialist care. Diagnosis
and management varied between centres and specialists.
Almost 10% of triple positive patients did not receive any
treatment at the time of medical record review. Major chal-
lenges according to specialists and patients were poor recogni-
tion of APS by health care professionals, fragmentation of
care and lack of accessible, reliable patient education and psy-
chosocial support.
Conclusion This study describes delayed diagnosis, variability
in management strategies and a burden placed on patients to
orchestrate their own care in APS care in The Netherlands.
Of note, almost 10% of triple positive patients did not receive
any treatment, despite this group of patients being at the
highest risk of recurrent thrombosis.
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Background Catastrophic antiphospholipid syndrome (CAPS) -
thrombotic microvasculopathy, characterized by involvement of
systems and organs with formation of their insufficiency. Ther-
apy of glucocorticoids and immunosuppressants with plasma-
pheresis and intravenous immunoglobulin demonstrates lack of
effectivity. Currently, there are reports of rituximab effective-
ness in APS and CAPS, but they are not numerous, especially
CAPS.
Methods Assessment of the rituximab effectiveness in patients
with resistant CAPS. We present the treatment results of two
patients with CAPS, who were treated in our clinic.
Results Patient V., 21, was admitted in the early postpartum
period. Diagnosis: Systemic lupus erythematosus, positivity for
ANA: ds-DNA, Sm. Secondary antiphospholipid syndrome
(positivity for b2-glycoprotein-1, cardiolipin, lupus anticoagu-
lant), catastrophic APS with multiorgan failure: epilepsy, sopor,
psychosis; acute renal injury, signs of acute respiratory distress
syndrome and hypocoagulation. SLEDAI score was 56 points,
GAPSS – 17 points. Pulse therapy with methylprednisolone,
cyclophosphamide, plasmapheresis and intravenous immunoglo-
bulin wasn’t effective enough. Rituximab course 375 mg/m2 1
time per week for 4 weeks was administered. Manifestations
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of CAPS in multiorgan failure form regressed 14 days after
the first administration, SLEDAI score decreased to 32 points,
GAPSS to 4 points. After 4 weeks complete B-cell depletion
was achieved. A month after the course of rituximab she
achieved remission, which lasts 4 years already. ANA and anti-
phospholipid antibodies weren’t detected.
Patient E., 20, with primary APS, cardiolipin positivity, b2-
glycoprotein-1 and lupus anticoagulant, thrombocytopenia,
livedo reticularis; CAPS-like thrombotic microangiopathy type
with damage to cerebral vessels, lung vessels, recurrent pulmo-
nary embolism for six months, deep leg vein thrombosis.
GAPSS activity before treatment was 17 points. Pulse therapy
wasn’t performed. Therapy rituximab 375 mg/m2 1 time per
week, 4 weeks was administered. Multiple organ failure also
regressed 10–14 days after 1 administration of rituximab.
GAPSS score decreased to 10 points. Incomplete B-cell deple-
tion was achieved.
Conclusion Thus, rituximab demonstrated high effectiveness in
CAPS in both cases. Rituximab allowed to reach multiple
organ failure regression and a persistent effect was achieved.
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Background Catastrophic antiphospholipid syndrome (CAPS)
is the most severe complication of antiphospholipid syndrome
(APS). Vitamin K antagonists (VKAs) are the reference treat-
ment for preventing relapsing thrombotic complications in
patients with APS, but direct oral anticoagulants (DOACs),
such as rivaroxaban, are nonetheless sometimes used in
patients with antiphospholipid antibody profiles or APS.
Recent studies showed that DOACs were associated with
more arterial thromboses among patients with APS. The
potential role of DOACs as a trigger factor of CAPS is not
known.
Methods We describe two patients who developed a CAPS in
the week following the institution of rivaroxaban.
Results We report the onset of definite CAPS in the week
following introduction of rivaroxaban treatment in two
patients, one with APS and the other with antiphospholipid
laboratory findings only. Both were triple positive for anti-
phospholipid antibodies. The affected organs were the heart,
kidneys, skin, and liver for Patient 1, and the heart, kid-
neys, skin, adrenal gland, and central nervous system for
Patient 2. The causative role of rivaroxaban is highly prob-
able given that (1) CAPS occurred rapidly after this treat-
ment was started, (2) an alternative trigger factor was found
in Patient 1 only (a colonoscopy), and (3) Patient 1 had
been clinically stable for 18 years with VKA as anticoagu-
lant treatment, while Patient 2 did not have APS and had
had no symptoms for 4 months (rivaroxaban had been
introduced because at a scheduled visit, she reported neuro-
logical symptoms that occurred four months before and
were retrospectively compatible with a brain transient ische-
mic accident). One similar case was reported in 2017, also
following the introduction of rivaroxaban, in a patient with
triple positive venous thrombotic APS who was stable for
years on warfarin and who developed definite CAPS
(involvement of the myocardium and adrenal glands as well
as a pulmonary embolism) in the week after rivaroxaban 20
mg daily replaced warfarin to meet the patient‘s desire for
a less burdensome treatment.1 Finally, in the randomized
study published by Ordi-Ros et al, one of the patients
treated with rivaroxaban developed a CAPS.2
Conclusions These two cases, as well as two previous reported
cases, underline the importance of avoiding DOACs in
patients with APS, especially those triple positive for antiphos-
pholipid antibodies. VKAs must remain the reference anticoa-
gulation treatment in this setting.
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Background Thrombocytopenia is a frequent hematological
manifestation in patients with systemic lupus erythematosus
(SLE), usually treated with glucocorticoids, immunosuppres-
sants (such as azathioprine and cyclophosphamide), intravenous
immunoglobulin (IVIG) or splenectomy.
Case report A 44-year-old woman diagnosed with SLE and
secondary antiphospholipid antibody syndrome was admitted
in our hospital, in July 2018, presenting severe renal and hae-
matological involvement. She underwent treatment with meth-
ylprednisolone, followed by prednisolone, and mycophenolate
mofetil, with no response. In August 2018, the patient started
haemodialysis, human immunoglobulin (transient response) and
plasmapheresis due to evidence of secondary thrombotic
microangiopathy. The refractory severe thrombocytopaenia and
lupus nephritis, justify two cycles of rituximab - platelet count
rising lasted for five months. Seven months later, the patient
presented pancytopenia and due to high hemorrhagic risk,
there was a switch from warfarin to LMWH (prophylactic
dosing). One month later, anti-coagulation was suspended due
to spontaneous intracranial bleeding. In August 2019, the
patient had an ischemic stroke of the right occipital lobe, sec-
ondary to APS, under prednisolone and hydroxychloroquine,
and with platelet count of 24.000/uL. Because of the bleeding
risk, no anti-aggregation was instituted, and she started tacroli-
mus - the initial good response disappeared two weeks later.
After consulting a rheumatology board, tacrolimus was kept
and rituximab repeated, regardless of the hypogammaglobuli-
nemia and no lymphocytes CD19+ count.
Conclusion We experienced a severe case of secondary throm-
bocytopenia, that was refractory to multiple therapeutic agents.
A reasonable response was obtained under rituximab. Tacroli-
mus is kept due to the reported cases of late effect. Ischaemic
stroke is a challenging condition in patients thrombocytopenic
and further clinical guidance is warranted.
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